BioPharmSignal logoBioPharmSignal

Biotech News

MaxCyte to Participate in Three Upcoming Investor Conferences

MaxCyte (MXCT)MaxCyteCompany update

ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced Company management will

Related news

MXCTMaxCyte2026-10-14 12:05 EST

MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance

MXCTMaxCyte2026-09-23 12:05 EST

MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer

OCGNOcugen2026-10-29 11:02 EST

Ocugen to Participate in Upcoming November Investor and Industry Conferences

OCGNOcugen2026-09-29 11:02 EST

Ocugen to Participate in Upcoming October Investor and Industry Conferences

RCKTRocket Pharmaceuticals2026-09-03 11:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

EDITEditas Medicine2026-09-01 13:00 EST

Editas Medicine to Participate in Upcoming Investor Conferences

PHARPharming Group2026-09-09 06:00 EST

Pharming Group to participate in September investor conferences

SRPTSarepta Therapeutics2026-10-26 20:30 EST

Sarepta Therapeutics to Present at Upcoming Investor Conferences

ABEOAbeona Therapeutics2026-09-02 11:30 EST

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

VYGRVoyager Therapeutics2026-09-01 12:00 EST

Voyager to Present at Upcoming Investor Conferences

View all latest news

MaxCyte

Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instrument family uses Flow Electroporation technology to introduce molecules into diverse cell types from laboratory through commercial scale...

Recent company news

MXCTMaxCyte2026-10-28 12:06 EST

MaxCyte to Participate in Three Upcoming Investor Conferences

MXCTMaxCyte2026-10-14 12:05 EST

MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance

MXCTMaxCyte2026-09-23 12:05 EST

MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer

MXCTMaxCyte2026-09-11 20:30 EST

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MXCTMaxCyte2026-08-19 12:05 EST

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

Stock data

Close
1.31 USD
Market cap
131.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States